Pharmacological properties and clinical outcomes of the anti-cancer drug, cabozantinib (CABOMETYX<sup>®</sup>)Tsuyoshi Osaka, Takahito Hara, Naoya Yamaguchi|Folia Pharmacologica Japonica|2021Cited by 1
Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft modelsTakahito Hara, Takayuki Yoshino, Megumi Morimoto et al.|BMC Cancer|2026Cited by 0